EGETIS THERAPEUTICS (Germany) Performance
| P0F Stock | EUR 0.67 0.02 2.90% |
On a scale of 0 to 100, EGETIS THERAPEUTICS holds a performance score of 7. The firm shows a Beta (market volatility) of -1.36, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning EGETIS THERAPEUTICS are expected to decrease by larger amounts. On the other hand, during market turmoil, EGETIS THERAPEUTICS is expected to outperform it. Please check EGETIS THERAPEUTICS's information ratio, total risk alpha, and the relationship between the coefficient of variation and jensen alpha , to make a quick decision on whether EGETIS THERAPEUTICS's price patterns will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in EGETIS THERAPEUTICS AB are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, EGETIS THERAPEUTICS reported solid returns over the last few months and may actually be approaching a breakup point. ...more
EGETIS |
EGETIS THERAPEUTICS Relative Risk vs. Return Landscape
If you would invest 56.00 in EGETIS THERAPEUTICS AB on March 22, 2024 and sell it today you would earn a total of 11.00 from holding EGETIS THERAPEUTICS AB or generate 19.64% return on investment over 90 days. EGETIS THERAPEUTICS AB is currently producing 0.3681% returns and takes up 4.0467% volatility of returns over 90 trading days. Put another way, 35% of traded stocks are less volatile than EGETIS, and 93% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
EGETIS THERAPEUTICS Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for EGETIS THERAPEUTICS's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as EGETIS THERAPEUTICS AB, and traders can use it to determine the average amount a EGETIS THERAPEUTICS's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.091
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | P0F | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.05 actual daily | 35 65% of assets are more volatile |
Expected Return
| 0.37 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average EGETIS THERAPEUTICS is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of EGETIS THERAPEUTICS by adding it to a well-diversified portfolio.
EGETIS THERAPEUTICS Fundamentals Growth
EGETIS Stock prices reflect investors' perceptions of the future prospects and financial health of EGETIS THERAPEUTICS, and EGETIS THERAPEUTICS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on EGETIS Stock performance.
| Return On Equity | -0.26 | |||
| Return On Asset | -0.14 | |||
| Shares Outstanding | 214.59 M | |||
| Debt To Equity | 0.01 % | |||
About EGETIS THERAPEUTICS Performance
To evaluate EGETIS THERAPEUTICS Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when EGETIS THERAPEUTICS generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare EGETIS Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand EGETIS THERAPEUTICS market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents EGETIS's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Egetis Therapeutics AB , a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rareniche diseases with unmet medical needs in the orphan drug segment. Egetis Therapeutics AB was founded in 2006 and is based in Stockholm, Sweden. EGETIS THERAPEUTICS operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 11 people.Things to note about EGETIS THERAPEUTICS performance evaluation
Checking the ongoing alerts about EGETIS THERAPEUTICS for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for EGETIS THERAPEUTICS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| EGETIS THERAPEUTICS has some characteristics of a very speculative penny stock | |
| EGETIS THERAPEUTICS had very high historical volatility over the last 90 days | |
| EGETIS THERAPEUTICS has high likelihood to experience some financial distress in the next 2 years | |
| About 61.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing EGETIS THERAPEUTICS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether EGETIS THERAPEUTICS's stock is overvalued or undervalued compared to its peers.
- Examining EGETIS THERAPEUTICS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating EGETIS THERAPEUTICS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of EGETIS THERAPEUTICS's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of EGETIS THERAPEUTICS's stock. These opinions can provide insight into EGETIS THERAPEUTICS's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for EGETIS Stock analysis
When running EGETIS THERAPEUTICS's price analysis, check to measure EGETIS THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EGETIS THERAPEUTICS is operating at the current time. Most of EGETIS THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of EGETIS THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EGETIS THERAPEUTICS's price. Additionally, you may evaluate how the addition of EGETIS THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |